Novartis Patient Support Program

GLEEVEC Reports: Patient Support Program

Enrollment Survey If you are taking GLEEVEC (imatinib mesylate) tablets for your Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), you qualify to enroll in a free support program from Novartis Oncology called GLEEVEC Reports. GLEEVEC Reports has been designed specifically to help people with Ph+ CML. Once you enroll in the program you will receive the latest information about Ph+ CML as well as personalized materials that will tell you: How Gleevec works What to expect from treatment How to manage your condition How to find support How to talk to your doctor Click Here to Enroll